CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 179 enrolled
Drug / intervention
PF-06826647 or Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03895372
NCT03895372Phase 2Completed
CompareCT.gov

A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Pfizer·interventional·Posted Mar 29, 2019·Updated Aug 27, 2021

In Brief

A Phase 2 clinical trial evaluating PF-06826647 or Placebo and PF-06826647 for Psoriasis. Completed, enrolled 179 participants across 45 sites in 4 countries.

Detailed Summary

This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, Japan, Poland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMar 29, 2019
Enrollment StartJun 27, 2019
Primary CompletionMay 21, 2020
Study CompletionNov 26, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.3 years ago

Interventions

PF-06826647 or Placebodrug

Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period

PF-06826647drug

Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period